Citations

Showing 10 of 108135 citations.

Genomic Observations of a Rare/Pathogenic SMAD3 Variant in Loeys–Dietz Syndrome 3 Confirmed by Protein Informatics and Structural Investigations
Richter, John E. , Samreen, Ayesha , Vadlamudi, Charitha , Helmi, Haytham , Mohammad, Ahmed N. , Wierenga, Klaas J. , Hines, Stephanie L., Caulfield, Thomas R. , Wierenga, Klaas, Hines, Stephanie, Caulfield, Thomas R , Samreen, Ayesha , Atwal, Paldeep S

Mayo Clinic

Medicina | May 15, 2019 | Volume: 55 | Issue: 5 | Pages: 137

10.3390/medicina55050137 | PMID 31096651 Get It

Background and objectives: Loeys–Dietz syndrome 3, also known as aneurysms-–osteoarthritis syndrome, is an autosomal dominant genetic connective tissue disease caused by pathogenic variants in SMAD3, a transcription factor involved in TGF-β signaling. This disorder is characterized by early-onset osteoarthritis and arterial aneurysms. Common features include scoliosis, uvula abnormalities, striae, and velvety skin. Materials and Methods: The pathogenicity of a variant of uncertain significance in the SMAD3 gene was evaluated (variant c.220C > T) through personalized protein informatics and molecular studies. Results: The case of a 44-year-old male, who was originally presumed to have Marfan syndrome, is presented. An expanded gene panel determined the probable cause to be a variant in SMAD3, c.220C > T (p.R74W). His case was complicated by a history of stroke, but his phenotype was otherwise characteristic for Loeys–Dietz syndrome 3. Conclusion: This case emphasizes the importance of comprehensive genetic testing to evaluate patients for connective tissue disorders, as well as the potential benefit of utilizing a protein informatics platform for the assessment of variant pathogenicity.
Transcranial Magnetic Stimulation Markers of Antidepressant Treatment in Adolescents With Major Depressive Disorder
Camsari, Deniz Doruk, Lewis, Charles P. , Sonmez, Ayse Irem , Nandakumar, Aiswarya Laks, Gresbrink, Marjorie A., Daskalakis, Zafiris J. , Doruk Camsari, Deniz, Croarkin, Paul E.

Mayo Clinic

International Journal of Neuropsychopharmacology | May 15, 2019 | Volume: 22 | Issue: 7 | Pages: 435-444

10.1093/ijnp/pyz021 | PMID 31095686 Get It

AbstractBackgroundThe goal of this study was to examine baseline transcranial magnetic stimulation measures of cortical inhibition and excitability in depressed patients and characterize their longitudinal posttreatment changes.MethodsFifteen adolescents (age 13–17 years) with moderate to severe major depressive disorder and 22 healthy controls (age 9–17) underwent single- and paired-pulse transcranial magnetic stimulation and clinical assessments. Transcranial magnetic stimulation measures included short-interval intracortical inhibition (2 and 4 milliseconds), long-interval intracortical inhibition (100, 150, and 200 milliseconds), cortical silent period, and intracortical facilitation (10, 15, and 20 milliseconds). Ten participants with major depressive disorder initiated antidepressant treatment or had dose adjustments. These participants were reassessed after treatment. Depression symptom severity was measured with the Children’s Depression Rating Scale, Revised. Robust regression modeling compared healthy and depressed adolescents at baseline. Relationships between changes in cortical inhibition and changes in depressive symptom severity were assessed in the depressed adolescents receiving antidepressant treatment.ResultsOur results revealed that at baseline, short-interval intracortical inhibition-2 was significantly reduced (Padj = .01) in depressed participants, suggesting impaired cortical inhibition compared with healthy controls. At follow-up, improvement in Children’s Depression Rating Scale, Revised scores correlated with improvement in short-interval intracortical inhibition-4 amplitude (greater inhibition) after antidepressant treatment (R2 = 0.63; P = .01).ConclusionsThese results suggest that cortical inhibition measures may have promise as biomarkers in adolescents treated for depression.
Recycling therapies for myeloma: The need for prospective trials
Kumar, Shaji , Kumar, Shaji K

Mayo Clinic

Cancer | May 15, 2019 | Volume: 125 | Issue: 17 | Pages: 2920-2922

10.1002/cncr.32177 | PMID 31090923 Get It

With the improving survival of patients with myeloma, there is a need for the development of multiple different drug combinations for continued treatment and disease control. Reusing previously used drugs, especially as part of new combinations, is an attractive strategy.
Sexual function after cancer: paying the price of survivorship
Kingsberg, Sheryl A. , Bober, Sharon L. , Faubion, Stephanie S.

Mayo Clinic

Climacteric | May 15, 2019 | Volume: 22 | Issue: 6 | Pages: 558-564

10.1080/13697137.2019.1606796 | PMID 31090466 Get It

Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma
Zhao, Shuang G. , Spratt, Daniel E. , Chang, S. Laura, Feng, Felix Y. , Speers, Corey , Carlson, Brett L. , Mladek, Ann C. , Lawrence, Theodore S. , Wahl, Daniel , Chang, S. Laura , Speers, Corey , Spratt, Daniel E , Lawrence, Theodore S , Mladek, Ann C , Zhao, Shuang G , Yu, Menggang , Kim, Michelle M. , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | May 15, 2019 | Volume: 21 | Issue: 9 | Pages: 1141-1149

10.1093/neuonc/noz090 | PMID 31121035 Get It

Abstract Background Predictive molecular biomarkers to select optimal treatment for patients with glioblastoma and other cancers are lacking. New strategies are needed when large randomized trials with correlative molecular data are not feasible. Methods Gene signatures (GS) were developed from 31 orthotopic glioblastoma patient-derived xenografts (PDXs), treated with standard therapies, to predict benefit from radiotherapy (RT-GS), temozolomide (Chemo-GS), or the combination (ChemoRT-GS). Independent validation was performed in a heterogeneously treated clinical cohort of 502 glioblastoma patients with overall survival as the primary endpoint. Multivariate Cox analysis was used to adjust for confounding variables and evaluate interactions between signatures and treatment. Results PDX models recapitulated the clinical heterogeneity of glioblastoma patients. RT-GS, Chemo-GS, and ChemoRT-GS were correlated with benefit from treatment in the PDX models. In independent clinical validation, higher RT-GS scores were associated with increased survival only in patients receiving RT (P = 0.0031, hazard ratio [HR] = 0.78 [0.66–0.92]), higher Chemo-GS scores were associated with increased survival only in patients receiving chemotherapy (P < 0.0001, HR = 0.66 [0.55–0.8]), and higher ChemoRT-GS scores were associated with increased survival only in patients receiving ChemoRT (P = 0.0001, HR = 0.54 [0.4–0.74]). RT-GS and ChemoRT-GS had significant interactions with treatment on multivariate analysis (P = 0.0009 and 0.02, respectively), indicating that they are bona fide predictive biomarkers. Conclusions Using a novel PDX-driven methodology, we developed and validated 3 platform-independent molecular signatures that predict benefit from standard of care therapies for glioblastoma. These signatures may be useful to personalize glioblastoma treatment in the clinic and this approach may be a generalizable method to identify predictive biomarkers without resource-intensive randomized trials.
Laryngeal Venous Malformation
Özgürsoy, Selmin Karataylı , Paz‐Fumagalli, Ricardo , Rutt, Amy, Karatayli Ozgursoy, Selmin, Paz-Fumagalli, Ricardo, Rutt, Amy L.

Mayo Clinic

Ear, Nose & Throat Journal | May 15, 2019 | Volume: 99 | Issue: 6 | Pages: 367-368

10.1177/0145561319840136 | PMID 31088295 Get It

β2‐Adrenergic Receptor Gene Affects the Heart Rate Response of β‐Blockers: Evidence From 3 Clinical Studies
Shahin, Mohamed H. , Rouby, Nihal El , Conrado, Daniela J., González, Daniel , Lobmeyer, Maximilian T. , Beitelshees, Amber L. , Boerwinkle, Eric , Gums, John G. , Chapman, Arlene B. , Pepine, Carl J. , Johnson, Julie A. , Beitelshees, Amber L. , Turner, Stephen T. , Gong, Yan , Chapman, Arlene B. , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

The Journal of Clinical Pharmacology | May 15, 2019 | Volume: 59 | Issue: 11 | Pages: 1462-1470

10.1002/jcph.1443 | PMID 31090079 Get It

Abstractβ‐Blockers’ heart rate (HR)‐lowering effect is an important determinant of the effectiveness for this class of drugs, yet it is variable among β‐blocker–treated patients. To date, genetic studies have revealed several genetic signals associated with HR response to β‐blockers. However, these genetic signals have not been consistently replicated across multiple independent cohorts. Here we sought to use data from 3 hypertension clinical trials to validate single‐nucleotide polymorphisms (SNPs) previously associated with the HR response to β‐blockers. Using linear regression analysis, we investigated the effects of 6 SNPs in 3 genes, including ADRB1, ADRB2, and GNB3, relative to the HR response following β‐blocker used in the PEAR (n = 757), PEAR‐2 (n = 368), and INVEST (n = 1401) trials, adjusting for baseline HR, age, sex, and ancestry. Atenolol was used in PEAR and INVEST, and metoprolol was used in PEAR‐2. We found that rs1042714 and rs1042713 in ADRB2 were significantly associated with HR response to both β‐blockers in whites (rs1042714 C‐allele carriers, meta‐analysis β = –0.95 beats per minute [bpm], meta‐analysis P = 3×10–4; rs1042713 A‐allele carriers, meta‐analysis β = –1.15 bpm, meta‐analysis P = 2×10–3). In conclusion, the results of our analyses provide strong evidence to support the hypothesis that rs1042714 and rs1042713 in the ADRB2 gene are important predictors of HR response to cardioselective β‐blockade in hypertensive patient cohorts.
Do simulation exercises ever fail?
Simon, Leslie V. , Felix, Heidi, Rosenbush, Kristin A., Simon, Leslie VanHorn, Felix, Heidi M, Felix, Heidi M, Chadha, Ryan

Mayo Clinic

The Clinical Teacher | May 14, 2019 | Volume: 17 | Issue: 2 | Pages: 207-208

10.1111/tct.13028 | PMID 31090197 Get It

TFAM Enhances Fat Oxidation and Attenuates High-Fat Diet–Induced Insulin Resistance in Skeletal Muscle
Koh, Jin‐Ho , Dasari, Surendra , Vučković, Ivan , Cooper, Shawna A. , Manjunatha, S , Ruegsegger, Gregory N. , Shulman, Gerald I. , Lanza, Ian R. , Johnson, Matthew L. , Henderson, Gregory C. , Manjunatha, Shankarappa, Shulman, Gerald I , Lanza, Ian R , Nair, K Sreekumaran , Vuckovic, Ivan , Cooper, Shawna A , LeBrasseur, Nathan K. , Nair, K. Sreekumaran

Mayo Clinic

Diabetes | May 14, 2019 | Volume: 68 | Issue: 8 | Pages: 1552-1564

10.2337/db19-0088 | PMID 31088855 Get It

Diet-induced insulin resistance (IR) adversely affects human health and life span. We show that muscle-specific overexpression of human mitochondrial transcription factor A (TFAM) attenuates high-fat diet (HFD)–induced fat gain and IR in mice in conjunction with increased energy expenditure and reduced oxidative stress. These TFAM effects on muscle are shown to be exerted by molecular changes that are beyond its direct effect on mitochondrial DNA replication and transcription. TFAM augmented the muscle tricarboxylic acid cycle and citrate synthase facilitating energy expenditure. TFAM enhanced muscle glucose uptake despite increased fatty acid (FA) oxidation in concert with higher β-oxidation capacity to reduce the accumulation of IR-related carnitines and ceramides. TFAM also increased pAMPK expression, explaining enhanced PGC1α and PPARβ, and reversing HFD-induced GLUT4 and pAKT reductions. TFAM-induced mild uncoupling is shown to protect mitochondrial membrane potential against FA-induced uncontrolled depolarization. These coordinated changes conferred protection to TFAM mice against HFD-induced obesity and IR while reducing oxidative stress with potential translational opportunities.
Surgical Management of Lower Extremity Lymphedema: A Comprehensive Review
Ciudad, Pedro , Sabbagh, M. Diya , Agko, Mouchammed , Huang, Tony Chieh‐Ting , Manrique, Oscar J. , L., Carmen Román, Reynaga, César, Delgado, Ricardo Vivancos, Mouchammed, Agko , Delgado, Ricardo, Maruccia, Michele , Chen, Hung‐Chi

Mayo Clinic

Indian Journal of Plastic Surgery | May 14, 2019 | Volume: 52 | Issue: 01 | Pages: 081-092

10.1055/s-0039-1688537 | PMID 31456616 Get It

Abstract Lymphedema refers to the accumulation of protein-rich fluid in the interstitial spaces. This can occur secondary to congenital malformation of the lymphatic channels or nodes or as a result of an insult that damages appropriately formed channels and nodes. Stagnant, protein-rich lymph initiates an inflammatory response that leads to adipocyte proliferation, fibrous tissue deposition, and increased susceptibility to infections. The end result is permanent disfigurement and dermal changes. Early and accurate diagnosis is essential, since lymphedema is a chronic and progressive problem. When lymphedema affects the lower extremity, it is important to manage it in a way that preserves function and mobility. Early diagnosis also allows for a proactive rather than reactive approach to treatment and utilization of novel physiologic procedures, such as lymphovenous anastomosis and vascularized lymph node transfer. Such interventions slow down disease progression and reduce morbidity by allowing the surgeon to salvage the remaining functional lymphatic channels. When physiologic procedures fail or when faced with a delayed presentation, the addition of excisional procedures can provide a more comprehensive treatment of this debilitating disease. The aim of this article is to review the most current concepts in the surgical management of lower extremity lymphedema.